• Latest
  • Trending

Sorrento Therapeutics: Very Bullish

March 26, 2019
Clean Energy Technology Finishes the Year Strong with Sizeable Order

Clean Energy Technology Finishes the Year Strong with Sizeable Order

November 6, 2019

Visium Technologies, Inc. (OTCMKTS: VISM) is a partner of Nutanix (NASDAQ: NTNX).

November 4, 2019

Qualibou Energy, Inc. (OTCMKTS: QALB) Heading To New Highs

November 1, 2019
Protected: BANGI, Inc. (OTCMKTS: BNGI) Growing Through Acquisitions

Protected: BANGI, Inc. (OTCMKTS: BNGI) Growing Through Acquisitions

November 1, 2019

InterActive Leisure Systems, Inc. (OTCMKTS: IALS) Spikes Up

October 30, 2019

Clancy Systems International, Inc. (OTCMKTS: CLSI) Reveals Financial Figures For 2019

October 30, 2019

Form Heading

Lists*

  • Setup menu at Appearance » Menus and assign menu to Top Bar Navigation
Thursday, December 5, 2019
Stockmarketrevolution
  • Home
  • MOMENTUM STOCKS
  • EARNINGS
  • ANALYSIS
  • IPO
  • Advertising
  • PREMIUM CONTENT
  • Home
  • MOMENTUM STOCKS
  • EARNINGS
  • ANALYSIS
  • IPO
  • Advertising
  • PREMIUM CONTENT
No Result
View All Result
Stockmarketrevolution
No Result
View All Result
Home MOMENTUM STOCKS

Sorrento Therapeutics: Very Bullish

Jacob Saphir by Jacob Saphir
March 26, 2019
in ANALYSIS, EARNINGS, MOMENTUM STOCKS
0
Share on FacebookShare on Twitter

In March 2019, running from $2 to more than $5, Sorrento Therapeutics (SRNE) seemed to seduce market participants. The market excitement was created by two stock catalyst. Firstly, it was related to the company’s presentation in Oppenheimer 29th Annual Healthcare Conference, in which nothing really was said and should have not pushed the share price up. With that, traders should understand that such type of presentations tend to create a lot of expectations and many market participants are ready to take some positions.

In addition, investors should have celebrated the most recent merger with Semnur Pharmaceuticals. It is expected to bring synergies and a new product candidate at Phase 3 of development, called S-102. This new non-opioid pain treatment for lumbar radicular is expected to be tested on 400 candidates and should increase the company’s market opportunity. With this feature in mind, the recent share price makes a lot of sense.   

Having mentioned this feature, investors should study the contractual obligations of Sorrento Therapeutics closely. According to the company’s annual report, Sorrento sold convertible notes and loans worth more than $400 million payable in three to five years. In December 2018, with $212 million in cash, the company may not have sufficient liquidity to pay its contractual obligations. This feature may push the stock price down in the long term.

Currently trading with a market capitalization of $616 million and reporting annual revenue of $21 million, the most beneficial on this name is that its revenue may increase in 2019. Remember that the company was expected to launch ZTlido from 4Q 2018. This feature along with the Phase 2 clinical trial for a second-generation anti-CEA CAR-T cell therapy could make the stock price move in 2019.

Sign up above to know more about the next steps of Sorrento Therapeutics!

Disclosure: We hold no position in Sorrento Therapeutics either long or short and we have not been compensated for this article. 

Share this:

  • Click to share on Twitter (Opens in new window)
  • Click to share on Facebook (Opens in new window)
  • Click to share on Google+ (Opens in new window)

Like this:

Like Loading...

Related

Tags: acquisitionbiotechmergerpharmaPhase 3Semnur PharmaceuticalsSorrento TherapeuticsSRNE
Previous Post

Globus Maritime Limited, 100% de rendimientos en solo unos días

Next Post

Silk Road Medical: It Seems Overvalued

Jacob Saphir

Jacob Saphir

Related Posts

Clean Energy Technology Finishes the Year Strong with Sizeable Order
ANALYSIS

Clean Energy Technology Finishes the Year Strong with Sizeable Order

November 6, 2019
ANALYSIS

Visium Technologies, Inc. (OTCMKTS: VISM) is a partner of Nutanix (NASDAQ: NTNX).

November 4, 2019
MOMENTUM STOCKS

Qualibou Energy, Inc. (OTCMKTS: QALB) Heading To New Highs

November 1, 2019
Next Post

Silk Road Medical: It Seems Overvalued

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Stockmarketrevolution

© 2017 Stock Market Revolution - The secret of freedom lies in educating people, whereas the secret of tyranny is in keeping them ignorant.

Navigate Site

  • About us
  • Advertise
  • Disclaimer

Follow Us

No Result
View All Result

© 2017 Stock Market Revolution - The secret of freedom lies in educating people, whereas the secret of tyranny is in keeping them ignorant.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In
%d bloggers like this: